Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Instagram Outage Disrupts Thousands of U.S. Users 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SOUTH PLAINFIELD, N.J., March 16, 2017 -- Advanced Molecular Diagnostics company, Admera Health, (www.admerahealth.com) announced today that its PGxOne™ Plus has received New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) approval for its 50 gene PGxOne™ Plus pharmacogenomics test. Admera had previously been approved by NYSDOH CLEP to offer its PGxOne™ Plus 25 gene version in the state of New York. With this approval, the updated PGxOne™ Plus 50 gene test is available in all 50 states.
PGxOne™ Plus is a Next Generation Sequencing (NGS) based test that predicts how a patient will respond to drug therapy based on their individual genetic makeup. Therapeutic areas include, but are not limited to, cardiology, psychiatry, pain management, and oncology. Examples of recommendations provided in the report are: consider alternatives (when specific drugs should be avoided), dosing adjustments, use with caution, or normal response expected.
“While we already had an earlier version of the PGxOne™ Plus test available to New York residents, we are thrilled to be able to offer them the full panel that interrogates nearly 200 different variants and provides clinically relevant recommendations for over 220 associated drugs,” said Guanghui Hu, PhD, President and CEO of Admera Health. He went on, “CLEP approval is a highly cherished milestone in the laboratory field and we are looking forward to our next submission.”
In addition to PGx testing, Admera Health offers clinical testing for the risk assessment and diagnosis of inherited cardiovascular diseases, cancer supportive therapy, and tumor profiling to guide selection of targeted therapies.
About Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is Admera’s mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. Admera health is committed to improving the health and well-being of the global community through the direct delivery of personalized, medically actionable results.
Admera Health Contact: Brady Millican, VP Business Development 908-222-0533 [email protected]
